These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 31553711)

  • 1. Health-related quality of life in Croatian general population and multiple myeloma patients assessed by the EORTC QLQ-C30 and EORTC QLQ-MY20 questionnaires.
    Ficko SL; Pejsa V; Zadnik V
    Radiol Oncol; 2019 Sep; 53(3):337-347. PubMed ID: 31553711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma.
    Proskorovsky I; Lewis P; Williams CD; Jordan K; Kyriakou C; Ishak J; Davies FE
    Health Qual Life Outcomes; 2014 Mar; 12():35. PubMed ID: 24618388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. General population normative values for the EORTC QLQ-C30 by age, sex, and health condition for the French general population.
    Pilz MJ; Loth FLC; Nolte S; Thurner AMM; Gamper EM; Anota A; Liegl G; Giesinger JM;
    J Patient Rep Outcomes; 2024 May; 8(1):48. PubMed ID: 38695992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. General Spanish population normative data analysis for the EORTC QLQ-C30 by sex, age, and health condition.
    Arraras JI; Nolte S; Liegl G; Rose M; Manterola A; Illarramendi JJ; Zarandona U; Rico M; Teiejria L; Asin G; Hernandez I; Barrado M; Vera R; Efficace F; Giesinger JM;
    Health Qual Life Outcomes; 2021 Aug; 19(1):208. PubMed ID: 34461909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quality of life is maintained with ixazomib maintenance in post-transplant newly diagnosed multiple myeloma: The TOURMALINE-MM3 trial.
    Schjesvold F; Goldschmidt H; Maisnar V; Spicka I; Abildgaard N; Rowlings P; Cain L; Romanus D; Suryanarayan K; Rajkumar V; Odom D; Gnanasakthy A; Dimopoulos M
    Eur J Haematol; 2020 May; 104(5):443-458. PubMed ID: 31880006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EORTC QLQ-C30 general population normative data for Italy by sex, age and health condition: an analysis of 1,036 individuals.
    Pilz MJ; Gamper EM; Efficace F; Arraras JI; Nolte S; Liegl G; Rose M; Giesinger JM;
    BMC Public Health; 2022 May; 22(1):1040. PubMed ID: 35610611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of the European Organisation for Research and Treatment of Cancer multiple myeloma module (EORTC QLQ-MY20): a review of the literature 25 years after development.
    Forde K; Cocks K; Wells JR; McMillan I; Kyriakou C;
    Blood Cancer J; 2023 May; 13(1):79. PubMed ID: 37193682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health-related quality of life and use of medication with anticholinergic activity in patients with multiple myeloma.
    de Lima MSR; de Pádua CAM; de Miranda Drummond PL; Silveira LP; Malta JS; Dos Santos RMM; Reis AMM
    Support Care Cancer; 2023 Jun; 31(7):379. PubMed ID: 37278732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Updated normative data for the EORTC QLQ-C30 in the general Dutch population by age and sex: a cross-sectional panel research study.
    de Ligt KM; Aaronson NK; Liegl G; Nolte S;
    Qual Life Res; 2023 Sep; 32(9):2477-2487. PubMed ID: 37031427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimation of minimally important differences and responder definitions for EORTC QLQ-MY20 scores in multiple myeloma patients.
    Sully K; Trigg A; Bonner N; Moreno-Koehler A; Trennery C; Shah N; Yucel E; Panjabi S; Cocks K
    Eur J Haematol; 2019 Nov; 103(5):500-509. PubMed ID: 31444815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Normative data for the EORTC QLQ-C30 from the Austrian general population.
    Lehmann J; Giesinger JM; Nolte S; Sztankay M; Wintner LM; Liegl G; Rose M; Holzner B;
    Health Qual Life Outcomes; 2020 Aug; 18(1):275. PubMed ID: 32787854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health-Related Quality of Life of Patients With Multiple Myeloma Treated in Routine Clinical Practice in France.
    Despiégel N; Touboul C; Flinois A; Saba G; Suzan F; Gonzalez-McQuire S; Bonnetain F
    Clin Lymphoma Myeloma Leuk; 2019 Jan; 19(1):e13-e28. PubMed ID: 30292736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-World Evaluation of Health-Related Quality of Life in Patients With Multiple Myeloma From Germany.
    Engelhardt M; Ihorst G; Singh M; Rieth A; Saba G; Pellan M; Lebioda A
    Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):e160-e175. PubMed ID: 33218965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. General population normative data for the EORTC QLQ-C30 health-related quality of life questionnaire based on 15,386 persons across 13 European countries, Canada and the Unites States.
    Nolte S; Liegl G; Petersen MA; Aaronson NK; Costantini A; Fayers PM; Groenvold M; Holzner B; Johnson CD; Kemmler G; Tomaszewski KA; Waldmann A; Young TE; Rose M;
    Eur J Cancer; 2019 Jan; 107():153-163. PubMed ID: 30576971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reference values of EORTC QLQ-C30, EORTC QLQ-BR23, and EQ-5D-5L for women with non-metastatic breast cancer at diagnosis and 2 years after.
    Miret C; Orive M; Sala M; García-Gutiérrez S; Sarasqueta C; Legarreta MJ; Redondo M; Rivero A; Castells X; Quintana JM; Garin O; Ferrer M;
    Qual Life Res; 2023 Apr; 32(4):989-1003. PubMed ID: 36630024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial.
    Andre T; Amonkar M; Norquist JM; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt CJA; Smith D; Garcia-Carbonero R; Sevilla I; De La Fouchardiere C; Rivera F; Elez E; Diaz LA; Yoshino T; Van Cutsem E; Yang P; Farooqui M; Le DT
    Lancet Oncol; 2021 May; 22(5):665-677. PubMed ID: 33812497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reliability and validity of the Greek QLQ-C30 and QLQ-MY20 for measuring quality of life in patients with multiple myeloma.
    Kontodimopoulos N; Samartzis A; Papadopoulos AA; Niakas D
    ScientificWorldJournal; 2012; 2012():842867. PubMed ID: 22919356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EORTC QLQ-C30 general population normative data for the United States.
    Rogge AA; Liegl G; Snyder C; Rose M; Nolte S;
    Eur J Cancer; 2024 May; 202():114030. PubMed ID: 38552543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of the psychometric properties of the Spanish version of EORTC QLQ-MY20 and evaluation of health-related quality of Life outcomes in patients with relapsed and/or refractory multiple myeloma in the real-world setting in Spain: results from the CharisMMa study.
    Dachs LR; Gaisán CM; Bustamante G; López SG; García EG; Persona EP; González-Calle V; Auzmendi MS; Pérez JMA; González Montes Y; Ríos Tamayo R; de Miguel Llorente D; Bernal LP; Mayol AS; Caro CC; Grande M; Fernández-Nistal A; Naves A; Miguel EMOS
    Leuk Lymphoma; 2023; 64(11):1847-1856. PubMed ID: 37539698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health-related quality of life scores of metastatic pancreatic cancer patients responsive to first line chemotherapy compared to newly derived EORTC QLQ-C30 reference values.
    Amin S; Joo S; Nolte S; Yoo HK; Patel N; Byrnes HF; Costa-Cabral S; Johnson CD
    BMC Cancer; 2022 May; 22(1):563. PubMed ID: 35596182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.